Rallybio
RLYB | NASDAQ
$15.43
-$0.29 (-1.84%)
At close: Nov 16, 2026, 4:00 PM ET
$15.38
-$0.05 (-0.33%)
After-hours:
Nov 16, 2026, 7:33 PM ET
-1.84%
(1D)No price chart data available for 1D timeframe.
Rating
45.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #374/1021 (Top 37%)
Key Statistics
Market Data
Market Cap $88.18M
1D Range
15.09 15.98
52W Range
4.33 17.22
Valuation (TTM)
PE 3.44
PB 0.96
EV/EBITDA -0.08
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $0.00
Cash Flow
FCF Yield 34.7%
SBC Adj. FCF Yield 32.2%
SBC Impact -7.2%
Margins
Gross Margin -742.9%
Operating Margin -4659.2%
FCF Margin 7053.9%
Growth (CAGR)
Revenue 3Y | 5Y -14.4% |
45.2%
Dil EPS 3Y | 5Y 237.4% |
64.3%
FCF 3Y | 5Y 220.9% |
56.7%
Returns
ROA 28.1%
ROE 36.4%
ROIC -20.8%
Financial Health
Net Cash
$90.69M
Current Ratio 28.87
Interest Coverage 0.00
Dividends
Div Yield 268.05%
Payout Ratio 923.2%
FCF Payout Ratio 0.0%
Loading financial charts...
Profile
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most adva...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Jul 29, 2021
Website www.rallybio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove RLYB